We report our experience with subcutaneous immunoglobulins (SCIg) in two subjects with chronic refractory inflammatory myopathies. The first was a 19-year-old male with ocular myositis refractory to previous different immunosuppressive therapies and with steroid-dependency. The second subjects was a 52-year-old woman with monocyclic chronic dematomyositis already successfully treated with prednisone, cyclosporine A and intravenous immunoglobulin (IVIG) with difficult venous access. SCIg (Vivaglobin (R): CSL Behring) was administered by a programmable pump. In this first six-month period of treatment, no relapse of the disease occurred. Both patients showed a clinical response and reported a good tolerance of the treatment. Our preliminary experience demonstrates the administration of SCIg is safe and beneficial in inflammatory myopathies.